Status:
COMPLETED
Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Lead Sponsor:
Medical University of South Carolina
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to understand if small proteins found on the surface of myeloma cells (called CXCR4 and CD47) or inside the myeloma cells (Pim kinases, sphingolipids, and pS6) can predict...
Eligibility Criteria
Inclusion
- A diagnosis of multiple myeloma or possible multiple myeloma who will have a bone marrow biopsy and aspirate
- Planned therapy with standard chemotreatment for multiple myeloma
- Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone survey available for staging purpose.
- ≥18 years old
Exclusion
- \< 18 years old
- Patients who will not receive chemotreatment
- Patients whose treatment records are not available
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT01410981
Start Date
August 1 2011
End Date
June 1 2014
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425